XSHE
002821
Market cap8.99bUSD
Oct 09, Last price
177.93CNY
1D
-1.52%
1Q
7.57%
Jan 2017
147.99%
IPO
635.86%
Name
Asymchem Laboratories Tianjin Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
Key people
Rui Yang
Co-Chief Executive Officer, Executive Director · since 2022
Chief Financial Officer, Chief Operating Officer, Executive Director · since 2024
Chaoyong Chen
Executive Vice President · since 2022
Liang Hong
Executive Vice President, Staff Elected Director · since 2025
Yingwei Jiang
Executive Vice President · since 2022
Xiangke Xu
Senior Vice President, Secretary of the Board · since 2023
Yan Zhou
Senior Vice President · since 2023
Chengyi Chen
Chief Technology Officer · since 2025
Hao Hong
Chairman of the Board, Chief Executive Officer · since 2022
Ye Song
Non-Executive Director · since 2011
Ting Zhang
Non-Executive Director · since 2023
Independent Non-Executive Director · since 2024
Kar Chung Lee
Independent Non-Executive Director · since 2021
Xuejiao Sun
Independent Non-Executive Director · since 2023
Weikai Xie
Independent Non-Executive Director · since 2025
Headquarters & legal address
洞庭三街6号
经济技术开发区
天津市, TJ 300457
CN
经济技术开发区
天津市, TJ 300457
CN
Other language
Asymchem Laboratories (Tianjin) Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||